Us Bancorp \De\ Esperion Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,083 shares of ESPR stock, worth $2,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,083

Previous 1,083 -0.0%

Holding current value

$2,523

Previous $2,000 50.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$1.2 - $1.76 $176 - $258	-147 Reduced 11.95%	1,083 $1,000
Q1 2023 May 09, 2023	SELL	$1.46 - $7.3 $3,663 - $18,315	-2,509 Reduced 67.1%	1,230 $1,000
Q4 2022 Feb 13, 2023	SELL	$5.09 - $8.5 $12,689 - $21,190	-2,493 Reduced 40.0%	3,739 $23,000
Q3 2022 Oct 27, 2022	BUY	$5.45 - $8.13 $3,182 - $4,747	584 Added 10.34%	6,232 $42,000
Q2 2022 Aug 01, 2022	BUY	$4.77 - $6.67 $5,514 - $7,710	1,156 Added 25.73%	5,648 $36,000
Q1 2022 May 11, 2022	BUY	$3.34 - $5.56 $10,681 - $17,780	3,198 Added 247.14%	4,492 $21,000
Q4 2021 Feb 11, 2022	SELL	$4.81 - $11.92 $15,771 - $39,085	-3,279 Reduced 71.7%	1,294 $6,000
Q3 2021 Nov 10, 2021	SELL	$11.34 - $21.37 $2,494 - $4,701	-220 Reduced 4.59%	4,573 $55,000
Q2 2021 Aug 05, 2021	SELL	$19.4 - $28.71 $12,609 - $18,661	-650 Reduced 11.94%	4,793 $101,000
Q1 2021 Apr 28, 2021	SELL	$25.12 - $36.89 $279,409 - $410,327	-11,123 Reduced 67.14%	5,443 $153,000
Q4 2020 Feb 04, 2021	SELL	$24.2 - $35.76 $133,801 - $197,717	-5,529 Reduced 25.02%	16,566 $431,000
Q3 2020 Nov 10, 2020	BUY	$31.18 - $52.71 $441,165 - $745,793	14,149 Added 178.06%	22,095 $821,000
Q2 2020 Aug 07, 2020	BUY	$30.04 - $51.31 $24,212 - $41,355	806 Added 11.29%	7,946 $408,000
Q1 2020 May 13, 2020	BUY	$27.44 - $73.84 $26,918 - $72,437	981 Added 15.93%	7,140 $225,000
Q4 2019 Feb 04, 2020	BUY	$35.4 - $59.82 $110,766 - $187,176	3,129 Added 103.27%	6,159 $368,000
Q3 2019 Nov 08, 2019	SELL	$34.47 - $47.53 $2,412 - $3,327	-70 Reduced 2.26%	3,030 $111,000
Q1 2019 May 08, 2019	SELL	$40.11 - $53.57 $300,825 - $401,775	-7,500 Reduced 70.75%	3,100 $124,000
Q4 2018 Feb 13, 2019	BUY	$36.99 - $59.11 $2,589 - $4,137	70 Added 0.66%	10,600 $487,000
Q3 2018 Nov 01, 2018	SELL	$40.74 - $51.41 $116,027 - $146,415	-2,848 Reduced 21.29%	10,530 $468,000
Q2 2018 Aug 08, 2018	SELL	$36.2 - $76.4 $107,441 - $226,755	-2,968 Reduced 18.16%	13,378 $524,000
Q1 2018 May 08, 2018	BUY	$65.94 - $80.76 $344,338 - $421,728	5,222 Added 46.94%	16,346 $1.18 Million
Q4 2017 Feb 02, 2018	BUY	$43.47 - $67.43 $3,173 - $4,922	73 Added 0.66%	11,124 $732,000
Q3 2017 Nov 13, 2017	BUY	$43.8 - $52.77 $484,033 - $583,161	11,051	11,051 $554,000

Others Institutions Holding ESPR

# of Institutions

207

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $155M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account